For successful application of genome editing technology using CRISPR/Cas9 system in clinical practice, it is necessary to achieve high efficiency of knock-in, the insertion of a genetic construct into a given locus in the genome of a target cell. One approach to increasing knock-in efficiency involves modifying donor DNA with the same targets for Cas9 (Cas9 targeting sequence, CTS) that are used for induction of double-strand breaks in the cell genome (the “double-cut donor” method). Another approach is based on introducing truncated targets for Cas9 (truncated CTS, tCTS), including a PAM site and 16 nucleotides proximal to it, into the donor DNA. Presumably, tCTS sites do not induce cleavage of the donor plasmid, but can support its transport into the nucleus by Cas9. However, the exact mechanisms for the increase in knock-in levels with both types of donor DNA modifications are unknown. Here, we evaluated the effect of these modifications on the knock-in efficiency of the MTC34 genetic construct encoding the HIV-1 fusion inhibitor, MT-C34 peptide, into the CXCR4 locus of the CEM/R5 T cell line. When full-length CTS sites were introduced into the donor plasmid DNA, the knock-in level increased twofold, regardless of the number of CTSs or their position relative to the donor sequence. Modifications of donor plasmids with tCTS sites did not affect knock-in levels. It was found that in vitro both types of sites were efficiently cleaved by Cas9. In order to study the mechanism of action of these modifications in detail, it is necessary to evaluate their cleavage in vitro and in vivo.
Read full abstract